ABCL
AbCellera Biologics Inc.- Healthcare
- Biotechnology
- $3.98B market cap
Forecast run · Nov 3, 2026Upside rank 123 of 3,203
Model Signal
ForecastQ Daily Probabilities
74.5%
64.3%
51.5%
Analyst Consensus
Recommendation2.08/5 Buy
Last price$12.27
Price target$16.33
Implied move+33.1%
Analysts12
ForecastQ Portfolios
ABCL is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.